A novel GLP-1 and FGF21 dual agonist has therapeutic potential for diabetes and non-alcoholic steatohepatitis

BACKGROUND: Fibroblast growth factor 21 (FGF21) has become a promising therapeutic target for metabolic diseases such as type 2 diabetes (T2D), obesity and non-alcoholic steatohepatitis. However, the clinical application of natural FGF21 molecule is limited because of its instability in vitro and sh...

詳細記述

保存先:
書誌詳細
出版年:EBioMedicine
主要な著者: Pan, Qi, Lin, Shushan, Li, Yu, Liu, Liang, Li, Xiaoping, Gao, Xianglei, Yan, Jiangyu, Gu, Baohua, Chen, Xiaofeng, Li, Wenjia, Tang, Xinfa, Chen, Chao, Guo, Lixin
フォーマット: Artigo
言語:Inglês
出版事項: Elsevier 2021
主題:
Research Paper
オンライン･アクセス:https://ncbi.nlm.nih.gov/pmc/articles/PMC7806870/
https://ncbi.nlm.nih.gov/pubmed/33421947
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.ebiom.2020.103202
タグ: タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!

類似資料